6 analysts give Zevra Therapeutics a "Buy" rating with an average 12-month target price of $20.25.
Zevra Therapeutics, a company developing prodrugs for serious medical conditions, has received a consensus "Buy" rating from 6 analyst firms with an average 12-month target price of $20.25. Its lead product candidates, KP1077IH and KP1077N, are in Phase 2 and Phase ½ clinical trials respectively. Institutional investors hold 35.03% of the company's stock and insiders have bought 22,000 shares over the last 90 days.
August 16, 2024
5 Articles